Periodontitis and smoking: the challenge of antimicrobial peptides

The treatment of periodontitis in smoking patients represents a daily clinical challenge. Smoking alters the balance of the oral microbiome, favouring the transition from a healthy ecosystem to a pathogenic and pro-inflammatory flora dominated by Gram-negative anaerobic species. Faced with the global challenge of antimicrobial resistance, this study explores a promising alternative: antimicrobial peptides (AMPs), key molecules of innate immunity.

The objective of this experimental work was to evaluate the efficacy of two synthetic derivatives of human cathelicidin LL37 — FK13a1-NH2 and KR12-NH2 — against target periodontal pathogens: Porphyromonas gingivalis, Fusobacterium nucleatum and Streptococcus oralis. The study specifically aimed to measure the antibacterial activity of these peptides when exposed to an environment loaded with cigarette smoke extracts (CSE).

The authors tested the hypothesis that these synthetic derivatives retain a significant bacterial inhibitory capacity despite the deleterious influence of tobacco. A crucial methodological point of the study lies in the definition of exposure: the maximum CSE concentration (100%) was calibrated to correspond precisely to the amount of smoke extracted from a single cigarette. The tests were conducted on bacteria in the planktonic phase as well as on the formation of monospecies and multispecies biofilms.

Methodology: An in vitro evaluation of the peptide-smoke synergistic effect

This experimental in vitro study evaluated the antibacterial efficacy of two synthetic derivatives of human cathelicidin LL37, FK13a1-NH2 and KR12-NH2, against three target bacterial strains: Porphyromonas gingivalis, Fusobacterium nucleatum and Streptococcus oralis.

The protocol incorporates a major environmental variable: cigarette smoke extract (CSE). The initial reference concentration (100%) was defined by the amount of smoke extracted from a single cigarette. The experimental design was structured as follows:

• Growth kinetics: Use of microdilution assays to measure the inhibition of bacteria in the planktonic phase.
• Evaluation of interactions: Checkerboard experiments to analyse the synergy between peptide doses (up to 500 μg/ml) and CSE concentrations (notably 50%).
• Biofilm models: Comparative analysis of the impact of peptides on mono-species biofilms and complex multi-species biofilms.
• Imaging and structural analysis: Use of confocal microscopy to precisely assess the reduction in biofilm thickness after exposure to the tested molecules.

The study compared bacterial survival and biofilm integrity in groups exposed to peptides alone, to CSE alone, or to both agents combined to simulate the periodontal environment of a smoking patient.

Antimicrobial efficacy in the planktonic phase

The study demonstrates that the two synthetic derivatives of human cathelicidin LL37, FK13a1-NH2 and KR12-NH2, effectively inhibit the growth of Porphyromonas gingivalis and Fusobacterium nucleatum when in the planktonic phase. A major finding concerns the interaction between these peptides and cigarette smoke extract (CSE).

Microdilution assay and the checkerboard method revealed a notable synergy. The combined application of KR12-NH2 and CSE produced the following results for the main periodontal pathogen:

Differential impact on biofilms

The efficacy of peptides varies considerably depending on the complexity of the bacterial organisation. Qualitative and quantitative observations highlight two distinct dynamics:

• Monospecies biofilms: Both peptides significantly reduced the thickness of biofilms formed by a single species.
• Multispecies biofilms: The impact on the complex structures comprising P. gingivalis, F. nucleatum and S. oralis was deemed less notable, suggesting increased protection conferred by the mature biofilm matrix.

Structural and mechanistic observations

Confocal imaging allowed the visualisation of the structural reduction of biofilms under the effect of the peptides. Concurrently, the study highlights a paradoxical effect of CSE: although smoke is a clinical risk factor, the smoke extract alone tends to reduce the growth of monospecies biofilms in vitro. This phenomenon could be explained by the suppression of the protective bacterial capsule induced by CSE, making the bacteria potentially more vulnerable to the direct action of the synthetic peptides.

In summary, the efficacy of these molecules remains robust even in an environment marked by tobacco exposure, particularly against Gram-negative anaerobes involved in periodontal tissue destruction.

Discussion: Mitigating tobacco-induced immunodeficiency

The major interest of this study lies in the ability of the FK13a1-NH2 and KR12-NH2 peptides to maintain robust antibacterial activity in an environment saturated with cigarette smoke extract (CSE). Clinically, smoking is a major risk factor that reduces the endogenous production of cathelicidin LL37, leaving the field open to the proliferation of anaerobic pathogens. By demonstrating that a concentration of 500 μg/ml of KR12-NH2 inhibits 98% of the growth of P. gingivalis even in the presence of 50% CSE, the results suggest a potential approach to chemically restore this compromised immune barrier.

Model limitations and biofilm resistance

A caveat is in order: while the effect is massive in the planktonic phase and on monospecific biofilms, it diminishes against complex multi-strain biofilms. This increased resistance confirms the physical and metabolic protection provided by the architecture of mature dental plaque. Notably: the study observes reduced growth of isolated biofilms in the presence of smoke. The authors attribute this to the suppression of the protective bacterial capsule by CSE, which could paradoxically facilitate peptide access to the bacterial membrane.

Summary of results

The study demonstrates that the synthetic peptide KR12-NH2 at 500 μg/ml, even when exposed to 50% cigarette smoke extract, succeeds in inhibiting 98% of the growth of P. gingivalis. However, while the efficacy is remarkable in the planktonic phase and on monospecies biofilms, it proves less notable on complex multispecies biofilms, illustrating the robustness of structured bacterial ecosystems.

In practical terms, for the practitioner:

• Explain the biological risk: Smoking does not merely stain teeth; it chemically neutralises the patient's innate antimicrobial peptides (LL37), rendering their periodontium vulnerable.
• An alternative to antibiotics: These synthetic peptides (FK13a1-NH2 and KR12-NH2) pave the way for targeted local treatments, effective regardless of the patient's smoking status and with no risk of bacterial cross-resistance.
• Root planing remains paramount: The limited efficacy of peptides on complex biofilms confirms that mechanical debridement remains the essential step to disrupt the physical protection of pathogens prior to any adjunctive therapy.

Technical glossary of the study

FK13a1-NH2 & KR12-NH2: Synthetic derivatives of human cathelicidin LL37. These next-generation peptides are central to the study for their ability to inhibit target periodontal pathogens, while offering a potential alternative to conventional antibiotics, particularly in smoking patients.

Antimicrobial Peptides (AMP): Molecules of innate immunity classified according to their mode of action. The study distinguishes cationic peptides, which disintegrate the bacterial membrane through electrostatic interaction, from non-membrane-bound peptides that target intracellular processes (protein or enzymatic synthesis).

CSE (Cigarette Smoke Extract): Experimental variable simulating tobacco exposure. In this protocol, the maximum concentration (100%) corresponds to the smoke extract of a single cigarette, enabling the evaluation of peptide efficacy in an oral environment chemically altered by smoking.

Porphyromonas gingivalis: Gram-negative anaerobic bacterium identified as a major periodontal pathogen. The study highlights that its prevalence and virulence are exacerbated by smoking, particularly via the upregulation of specific adhesion proteins (FimA).

Multi-species biofilms: Complex microbial communities characterised by physical and metabolic interactions. The results of the study reveal that while the peptides effectively reduce the thickness of single-species biofilms, their impact is significantly less pronounced on these more resistant polymicrobial structures.

Fusobacterium nucleatum: Abundant oral bacterium playing a key "bridge" role in dental plaque formation. Tobacco exposure increases its abundance, regardless of the patient's initial periodontal status, making it a priority target for new peptide treatments.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always verifying with the original source article. Delynov disclaims all liability regarding the use of this information. This document is not intended for patients or the general public.